Literature DB >> 8025345

Platelet-vessel wall interaction: role of nitric oxide, prostaglandins and endothelins.

T F Lüscher1.   

Abstract

Platelets can interact with the blood vessel wall in numerous ways. By releasing vasoactive substances such as adenosine tri- and diphosphate as well as serotonin, platelets can stimulate the formation of nitric oxide and prostacyclin within endothelial cells. Under physiological conditions, this may provide an important protective mechanism providing platelet inhibition and increased local blood flow at sites of platelet activation. In addition, platelets also can stimulate the formation of the vasoconstrictor peptide endothelin-1 within endothelial cells. On the other hand, platelet-derived substances such as thromboxane and serotonin can activate vascular smooth muscle cells and cause profound vasoconstriction. Platelet-vessel wall interaction is normally very low due to protective mechanisms. In disease states, however, endothelial dysfunction increases platelet-vessel wall interaction. Low-density lipoproteins markedly reduced endothelium-dependent relaxations to aggregating platelets and serotonin. Even more marked changes in endothelial function occur in atherosclerosis. These functional alterations of platelet-vessel wall interaction may play an important role in the pathogenesis of cardiovascular disease.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8025345     DOI: 10.1016/s0950-3536(05)80191-x

Source DB:  PubMed          Journal:  Baillieres Clin Haematol        ISSN: 0950-3536


  2 in total

1.  Ultrastructural localisation of nitric oxide synthase, endothelin and binding sites of lectin (from Bandeirea simplicifolia) in the rat carotid artery after balloon catheter injury.

Authors:  A Loesch; P Milner; S C Anglin; R Crowe; S Miah; J R McEwan; G Burnstock
Journal:  J Anat       Date:  1997-01       Impact factor: 2.610

2.  Effect of diadenosine phosphates on human umbilical vessels: novel platelet-derived vasoconstrictors.

Authors:  G Davies; R J MacAllister; R G Bogle; P Vallance
Journal:  Br J Clin Pharmacol       Date:  1995-08       Impact factor: 4.335

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.